文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

真性红细胞增多症的诊疗:基于循证的非化疗管理

How I treat polycythemia vera.
PubMed 文献 · Blood · 2019-05-31

本文以临床案例为基础,综述真性红细胞增多症(PV)的诊断与管理。PV 为克隆性造血干细胞疾病,JAK2 突变驱动但仅 PV 出现红细胞增多,血浆容量扩张可掩盖红细胞增多而增加诊断难度。作者主张以循证方式、不依赖化疗进行诊疗,多数患者可获长期良好生活。

要点

  • PV 为克隆性造血干细胞肿瘤,驱动突变导致形态功能正常的血细胞过度生成。
  • PV 与 ET、PMF 共享 JAK2 突变,但红细胞增多仅见于 PV。
  • PV 血浆容量常扩张,可掩盖红细胞增多,忽视此点将增加诊断难度。

核心结论

  • 基于过去一个世纪的认识,大多数 PV 患者可享有长期且有产出的生活。
  • 作者以临床案例描述如何以循证方式、不依赖化疗来诊断和管理 PV。

研究设计与样本

  • 综述,以临床案例阐述 PV 的诊断与管理,未报告系统检索范围。

主要发现

  • PV 为克隆性造血干细胞疾病,属肿瘤,但驱动突变导致形态和功能正常的血细胞过度生成。
  • PV 起病可仅表现为红细胞增多、白细胞增多、血小板增多或任意组合,伴脾大或骨髓纤维化,真性全髓病可数年才出现。
  • PV 与原发性血小板增多症和原发性骨髓纤维化共享 JAK2 突变,但红细胞增多仅见于 PV。
  • 与继发性红细胞增多不同,PV 血浆容量常扩张,可掩盖红细胞增多,忽视此点使诊断困难。
  • PV 并非单一疾病:女性患者 deregulate 的基因较少且临床行为与男性不同,部分 PV 患者遗传上易呈侵袭性病程。

临床怎么用

  • 诊断 PV 时需考虑血浆容量扩张可掩盖红细胞增多这一要点。
  • 作者主张以循证方式管理 PV,不依赖化疗。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since its discovery, polycythemia vera (PV) has challenged clinicians responsible for its diagnosis and management and scientists investigating its pathogenesis. As a clonal hematopoietic stem cell (HSC) disorder, PV is a neoplasm but its driver mutations result in overproduction of morphologically and functionally normal blood cells. PV arises in an HSC but it can present initially as isolated erythrocytosis, leukocytosis, thrombocytosis, or any combination of these together with splenomegaly or myelofibrosis, and it can take years for a true panmyelopathy to appear. PV shares the same JAK2 mutation as essential thrombocytosis and primary myelofibrosis, but erythrocytosis only occurs in PV. However, unlike secondary causes of erythrocytosis, in PV, the plasma volume is frequently expanded, masking the erythrocytosis and making diagnosis difficult if this essential fact is ignored. PV is not a monolithic disorder: female patients deregulate fewer genes and clinically behave differently than their male counterparts, while some PV patients are genetically predisposed to an aggressive clinical course. Nevertheless, based on what we have learned over the past century, most PV patients can lead long and productive lives. In this review, using clinical examples, I describe how I diagnose and manage PV in an evidence-based manner without relying on chemotherapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Spivak JL. How I treat polycythemia vera. Blood. 2019. PMID: 31151982. doi:10.1182/blood.2018834044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。